Comparing mRNA expression between carrier treated and sorafenib treated Myc/NrasG12V liver tumors
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP295093
下载链接
链接失效反馈官方服务：
资源简介：
To profile determinants of sensitivity and resistance towards the multikinase inhibitor sorafenib in liver cancer (HCC), we generated HCCs with elevated MYC expression and activated Raf-MEK-ERK signaling. To trigger tumor development, we co-delivered transposable elements encoding for Myc and oncogenic NrasG12V via hydrodynamic injection into the hepatocytes of C57BL/6 wildtype mice. To characterize the response of Myc/NrasG12V HCCs towards sorafenib, we analyzed their transcriptomes after three weeks of sorafenib or carrier treatment. Overall design: mRNA expression of carrier treated and sorafenib treated Myc/NrasG12V liver tumors was compared via mRNAseq analysis
创建时间：
2020-12-04
